Ionotropic Glutamate Receptors

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 44: Line 44:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <scene name='Ionotropic_Glutamate_Receptors/Lbd_opening/3'>The LBD</scene> is located just above the TMD and has an overall <scene name='Ionotropic_Glutamate_Receptors/Lbd_opening_two/2'>two-fold axis of symmetry</scene>. Within each LBD lies the so-called <scene name='Ionotropic_Glutamate_Receptors/Lbd_clamshell_open/1'>“clamshell”</scene>. This structure is responsible for <scene name='Ionotropic_Glutamate_Receptors/Lbd_clamshell_open_bound/1'>binding glutamate</scene> and “sensitizing” the receptor to allow passage of cations through the channel. Residues Pro 89, Leu 90, Arg 96, Ser 142, & Glu 193 among others (residue numbers in [[1ftj]] model), which are responsible for <scene name='Ionotropic_Glutamate_Receptors/Binding/1'>tightly binding glutamate</scene> within the clamshell, are highly conserved. Glutamate binding causes a <scene name='Ionotropic_Glutamate_Receptors/Two/2'>conformational change</scene> (<scene name='Ionotropic_Glutamate_Receptors/Two_top/1'>Alternate View</scene>) in the LBD which pulls the M3 helices in the TMD apart, opening the channel and allowing for cation passage. A morph of the conformational change in the LBD upon glutamate binding can be <scene name='Ionotropic_Glutamate_Receptors/Morph_binding/3'>seen here</scene>. Uniquely, due to the varied importance of the homotetramer subunits due to symmetry mismatch, the interaction of glutamate with the distal subunits is predicted to result in a greater conformational change. Thus these distal subunits play a more critical role in channel sensitization and activation.<ref name="Sobo"/>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <scene name='Ionotropic_Glutamate_Receptors/Lbd_opening/3'>The LBD</scene> is located just above the TMD and has an overall <scene name='Ionotropic_Glutamate_Receptors/Lbd_opening_two/2'>two-fold axis of symmetry</scene>. Within each LBD lies the so-called <scene name='Ionotropic_Glutamate_Receptors/Lbd_clamshell_open/1'>“clamshell”</scene>. This structure is responsible for <scene name='Ionotropic_Glutamate_Receptors/Lbd_clamshell_open_bound/1'>binding glutamate</scene> and “sensitizing” the receptor to allow passage of cations through the channel. Residues Pro 89, Leu 90, Arg 96, Ser 142, & Glu 193 among others (residue numbers in [[1ftj]] model), which are responsible for <scene name='Ionotropic_Glutamate_Receptors/Binding/1'>tightly binding glutamate</scene> within the clamshell, are highly conserved. Glutamate binding causes a <scene name='Ionotropic_Glutamate_Receptors/Two/2'>conformational change</scene> (<scene name='Ionotropic_Glutamate_Receptors/Two_top/1'>Alternate View</scene>) in the LBD which pulls the M3 helices in the TMD apart, opening the channel and allowing for cation passage. A morph of the conformational change in the LBD upon glutamate binding can be <scene name='Ionotropic_Glutamate_Receptors/Morph_binding/3'>seen here</scene>. Uniquely, due to the varied importance of the homotetramer subunits due to symmetry mismatch, the interaction of glutamate with the distal subunits is predicted to result in a greater conformational change. Thus these distal subunits play a more critical role in channel sensitization and activation.<ref name="Sobo"/>
====Pharmaceutical Relevance====
====Pharmaceutical Relevance====
-
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As mentioned previously, extensive investigation into the [[Pharmaceutical drugs|pharmaceutical potential]] of IGluRs as a target for treating various ailments including [[Autism Spectrum Disorders]] symptoms is ongoing. In addition to agents which reduce neural excitation such as benzodiazapines, small molecules that potentiate AMPA receptor currents have been proven to reduce cognitive deficits caused by neurodegenerative diseases such as [[Alzheimer's Disease]].<ref name="Purcel"/> Modulators such as aniracetam and CX614 <scene name='Ionotropic_Glutamate_Receptors/Locked_into_place/2'>bind on the backside</scene> ([[2al4]]) of the ligand-binding core through interactions with a “proline ceiling” and a “serine floor”, stabilizing the closed-clamshell conformation. Although these compounds would likely be ineffective in the case of Autism patients because they slow the deactivation of the IGluR channels, this class of compounds has exciting therapeutic potential.<ref name="Jin"/>. The glutamate receptor inhibitor [[Diuril]] is used as drug in cases of hypertension, edema, diabetes insipidus and kidney stones<ref>PMID: 13580922</ref>.
+
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As mentioned previously, extensive investigation into the [[Pharmaceutical drugs|pharmaceutical potential]] of IGluRs as a target for treating various ailments including [[Autism Spectrum Disorders]] symptoms is ongoing. In addition to agents which reduce neural excitation such as benzodiazapines, small molecules that potentiate AMPA receptor currents have been proven to reduce cognitive deficits caused by neurodegenerative diseases such as [[Alzheimer's Disease]].<ref name="Purcel"/> See also [[Memantine]]. Modulators such as aniracetam and CX614 <scene name='Ionotropic_Glutamate_Receptors/Locked_into_place/2'>bind on the backside</scene> ([[2al4]]) of the ligand-binding core through interactions with a “proline ceiling” and a “serine floor”, stabilizing the closed-clamshell conformation. Although these compounds would likely be ineffective in the case of Autism patients because they slow the deactivation of the IGluR channels, this class of compounds has exciting therapeutic potential.<ref name="Jin"/>. The glutamate receptor inhibitor [[Diuril]] is used as drug in cases of hypertension, edema, diabetes insipidus and kidney stones<ref>PMID: 13580922</ref>.
==3D structures of glutamate receptor ==
==3D structures of glutamate receptor ==

Revision as of 10:59, 30 April 2023

Structure of the ionotropic glutamate receptor tetramer, GluA2, (3kg2)

Drag the structure with the mouse to rotate

Contents

Page Development

This article was developed based on lectures given in Chemistry 543 by Prof. Clarence E. Schutt at Princeton University.

Topic Page on Glutamate Receptor GluA2 structure

There is a topic page describing in detail the GluA2 structure described in 3kg2. The page is meant to complement the original publication of the structure by Sobolevsky et al.[2][9] with matching colors, etc..

See Also

References

  1. 1.0 1.1 1.2 Jin R, Clark S, Weeks AM, Dudman JT, Gouaux E, Partin KM. Mechanism of positive allosteric modulators acting on AMPA receptors. J Neurosci. 2005 Sep 28;25(39):9027-36. PMID:16192394 doi:25/39/9027
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 Sobolevsky AI, Rosconi MP, Gouaux E. X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor. Nature. 2009 Dec 10;462(7274):745-56. Epub . PMID:19946266 doi:10.1038/nature08624
  3. 3.0 3.1 3.2 3.3 Purcell AE, Jeon OH, Zimmerman AW, Blue ME, Pevsner J. Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology. 2001 Nov 13;57(9):1618-28. PMID:11706102
  4. Welsh JP, Ahn ES, Placantonakis DG. Is autism due to brain desynchronization? Int J Dev Neurosci. 2005 Apr-May;23(2-3):253-63. PMID:15749250 doi:10.1016/j.ijdevneu.2004.09.002
  5. Zuo J, De Jager PL, Takahashi KA, Jiang W, Linden DJ, Heintz N. Neurodegeneration in Lurcher mice caused by mutation in delta2 glutamate receptor gene. Nature. 1997 Aug 21;388(6644):769-73. PMID:9285588 doi:10.1038/42009
  6. Rubenstein JL, Merzenich MM. Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav. 2003 Oct;2(5):255-67. PMID:14606691
  7. Jin R, Singh SK, Gu S, Furukawa H, Sobolevsky AI, Zhou J, Jin Y, Gouaux E. Crystal structure and association behaviour of the GluR2 amino-terminal domain. EMBO J. 2009 Jun 17;28(12):1812-23. Epub 2009 May 21. PMID:19461580 doi:10.1038/emboj.2009.140
  8. HERRMANN GR, HEJTMANCIK MR, GRAHAM RN, MARBURGER RC. A new superior oral diuretic drug, chlorothiazide (diuril); clinical evaluation. Tex State J Med. 1958 Sep;54(9):639-45. PMID:13580922
  9. Wollmuth LP, Traynelis SF. Neuroscience: Excitatory view of a receptor. Nature. 2009 Dec 10;462(7274):729-31. PMID:20010675 doi:10.1038/462729a
Personal tools